Dean Atkinson, MD
Allergy & Immunology · Oklahoma City, OKNPI 1700883808
Payments from drug & device makers
Across 425 payments — averaging $29.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$4K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$871
- Sanofi$748
- GSK$738
- CSL Behring$695
- plus $4K from 27 others
What the payments were for
- Consulting fees$2,50020%
- Travel & lodging$1,1589%
- Food & beverage$8,71969%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 25 | $4,071 |
| AstraZeneca | 60 | $1,925 |
| Regeneron Healthcare Solutions, Inc. | 46 | $871 |
| Sanofi | 45 | $748 |
| GSK | 67 | $738 |
| CSL Behring | 34 | $695 |
| Novartis | 21 | $455 |
| Genentech USA, Inc. | 14 | $446 |
| Pfizer | 19 | $347 |
| Alk-abello, Inc | 8 | $316 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $275 |
| Kaleo, Inc. | 15 | $260 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $210 |
| Sanofi-aventis U.S. LLC | 10 | $186 |
| Grifols USA, LLC | 4 | $178 |
| Biocryst US Sales Co., LLC | 8 | $141 |
| Pharming Healthcare, Inc. | 5 | $129 |
| AbbVie | 3 | $79 |
| Blueprint Medicines Corporation | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Amgen | 3 | $58 |
| Octapharma USA, Inc. | 2 | $45 |
| Hikma Pharmaceuticals USA | 2 | $39 |
| Genentech, Inc. | 1 | $35 |
| Ionis Pharmaceuticals, Inc. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Dermavant Sciences, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Greer Laboratories, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $11 |
| Cycle Pharmaceuticals Inc | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 28 | $633,917 |
| Dupixent SyringeDupilumab | 26 | $104,793 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $67,074 |
| Spiriva RespimatTiotropium Bromide | 58 | $42,496 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $32,702 |
| Advair HfaFluticasone Propion/Salmeterol | 66 | $30,946 |
| Epinephrine | 159 | $29,706 |
| DuleraMometasone/Formoterol | 41 | $19,718 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 103 | $17,869 |
| Montelukast Sodium | 718 | $15,852 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $14,085 |
| Budesonide | 16 | $9,714 |
| Azelastine Hcl | 232 | $9,393 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 277 | $8,102 |
| Wixela InhubFluticasone Propion/Salmeterol | 51 | $7,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $695 | $633,91728 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $738 | $108,651170 claims |
| Hikma Pharmaceuticals USAEpinephrine | $39 | $29,706159 claims |
| AstraZenecaSymbicort | $1,925 | $14,08541 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $60 | $4,20913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Oklahoma City
- Amy DarterOklahoma City$559K
- Shahan StutesOklahoma City$43K
- Laura ChongOklahoma City$9K
- Richard HatchOklahoma City$8K
- Patricia OverhulserOklahoma City$6K
- Warren FilleyOklahoma City$345
- Iftikhar HussainTulsa$7.1M
- Bret HaymoreBroken Arrow$368K
- Nalin UgEdmond$93K
- Weyman LamTulsa$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.